Overview

Drug Interaction Study

Status:
Recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
This is a single center, 2-Part, Phase 1, open-label, fixed-sequence, drug-drug interaction study designed to compare the PK of ecopipam when administered alone and in combination with itraconazole (Part 1) or rifampicin (Part 2) in healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Emalex Biosciences Inc.
Collaborators:
Cambridge Cognition Ltd
Syneos Health
Treatments:
Ecopipam
Itraconazole
Rifampin